| Toggle Summary
|
Minerva Neurosciences Reports Positive Data Showing an Analog of Minerva's MIN-301 Compound Improves Symptoms of Parkinson's Disease in Primates
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences Announces Completion of Development and Final Selection of Once-Daily Dose Formulation of MIN-101 for Its Schizophrenia Program
New Formulation to be Used in Planned Phase 2b Clinical Trial Has Been Developed to Offer Improved Safety, Tolerability and Pharmacokinetic Profile
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences Appoints Dr. Remy Luthringer as CEO
|
View HTML
|
| Toggle Summary
|
Dr. Remy Luthringer, Minerva President and Chief Scientific Officer, to Present at CNS Summit
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences Reports Third Quarter 2014 Financial Results
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences to Host Third Quarter 2014 Financial Results Webcast and Conference Call
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences Announces Completion of FDA Review of Investigational New Drug Application for MIN-202 and Plans for First U.S.-Based Clinical Trial
Bioavailability Study in U.S. for Investigational Therapy in Development for Treatment of Insomnia to be Initiated
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences to Present at Baird 2014 Health Care Conference
|
View HTML
|
| Toggle Summary
|
Mark S. Levine Joins Minerva Neurosciences as VP and General Counsel
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences Reports Second Quarter 2014 Financial Results
|
View HTML
|
